Welcome to the Bioasis Technologies Hub On AGORACOM

Free
Message: Sangamo In Vivo Gene Editing for Enzyme/Protein Replacement Therapy

Thanks to JD on the Stockhouse board for bringing this milestone to our attention. Sangamo is using zinc-finger nuclease gene editing tools with an adeno-associated viral (AAV) vector delivery vehcile in vivo in human trials to correct enzyme deficiency diseases such as Hunter syndrome (MPS II). In short, this allows them to genetically edit some of the liver cells and replace the albumin genetic locus with that of the IDS gene that is mutated/deficient in MPS II. The end result is turning the liver into a IDS generating factory to give long-term enzyme replacement w/o regular infusion of recombinant IDS enzyme. 

How does this tie into biOasis? Well, regardless of the liver making the IDS enzyme or the patient receiving infusion of IDS enzyme, the blood brain barrier is an obstactle for getting the enzyme into the brain. The xB3 (formerly Transcendpep, Mtfp) could be a key for augmenting this Sangamo approach to enable sufficient enzyme replacement to the brain.

Sangamo claims a major milestone in gene editing, treating first patient with its zinc finger nuclease tech

A human has been injected with gene-editing tools to cure his disabling disease. Here’s what you need to know

In vivo genome editing of the albumin locus as a platform for protein replacement therapy.

Share
New Message
Please login to post a reply